Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

210 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radical prostatectomy cancer grade and percentage of Gleason pattern 4 estimated by global vs individual tumor grading correlate differently with the risk of biochemical recurrence in Grade Group 2 and 3 cancers.
Kryvenko ON, Epstein JI, Merhe A, Iakymenko OA, De Almeida E Silva Junior R, Chanamolu DK, Briski LM, Kwon D, Nemov I, Punnen S, Pollack A, Stoyanova R, Parekh DJ, Jorda M, Gonzalgo ML. Kryvenko ON, et al. Among authors: stoyanova r. Am J Clin Pathol. 2024 Jul 5;162(1):51-61. doi: 10.1093/ajcp/aqae003. Am J Clin Pathol. 2024. PMID: 38412318
Radiogenomic profiling of prostate tumors prior to external beam radiotherapy converges on a transcriptomic signature of TGF-β activity driving tumor recurrence.
Ku AT, Shankavaram U, Trostel SY, Zhang H, Sater HA, Harmon SA, Carrabba NV, Liu Y, Wood BJ, Pinto PA, Choyke PL, Stoyanova R, Davicioni E, Pollack A, Turkbey B, Sowalsky AG, Citrin DE. Ku AT, et al. Among authors: stoyanova r. medRxiv [Preprint]. 2023 May 2:2023.05.01.23288883. doi: 10.1101/2023.05.01.23288883. medRxiv. 2023. PMID: 37205576 Free PMC article. Preprint.
Clinical-Genomic Risk Group Classification of Suspicious Lesions on Prostate Multiparametric-MRI.
Stoyanova R, Zavala-Romero O, Kwon D, Breto AL, Xu IR, Algohary A, Alhusseini M, Gaston SM, Castillo P, Kryvenko ON, Davicioni E, Nahar B, Spieler B, Abramowitz MC, Dal Pra A, Parekh DJ, Punnen S, Pollack A. Stoyanova R, et al. Cancers (Basel). 2023 Oct 31;15(21):5240. doi: 10.3390/cancers15215240. Cancers (Basel). 2023. PMID: 37958414 Free PMC article.
Evaluating 4Kscore's role in predicting progression on active surveillance for prostate cancer independently of clinical information and PIRADS score.
Hougen HY, Reis IM, Han S, Prakash NS, Thomas J, Stoyanova R, Castillo RP, Kryvenko ON, Ritch CR, Nahar B, Gonzalgo ML, Gaston SM, Abramowitz MC, Dal Pra A, Mahal BA, Pollack A, Parekh DJ, Punnen S. Hougen HY, et al. Among authors: stoyanova r. Prostate Cancer Prostatic Dis. 2024 Sep 27. doi: 10.1038/s41391-024-00898-w. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39333697
Integrated framework for quantitative T2-weighted MRI analysis following prostate cancer radiotherapy.
Zacharaki EI, Breto AL, Algohary A, Wallaengen V, Gaston SM, Punnen S, Castillo P, Pattany PM, Kryvenko ON, Spieler B, Ford JC, Abramowitz MC, Dal Pra A, Pollack A, Stoyanova R. Zacharaki EI, et al. Among authors: stoyanova r. Phys Imaging Radiat Oncol. 2024 Oct 24;32:100660. doi: 10.1016/j.phro.2024.100660. eCollection 2024 Oct. Phys Imaging Radiat Oncol. 2024. PMID: 39563782 Free PMC article.
Assessing the Molecular Heterogeneity of Prostate Cancer Biopsy Sampling: Insights from the MAST Trial.
Ajami T, Yu H, Porto JG, Prakash NS, Williams A, Avda Y, Malpani A, Mendiola DF, Freitas PFS, Khandekar A, Swain S, Gaston S, Mahal B, Cortizas E, Szczotka Z, Gerard T, Kava B, Stoyanova R, Kryvenko ON, Castillo P, Ritch CR, Nahar B, Gonzalgo ML, Pollack A, Parekh DJ, Punnen S. Ajami T, et al. Among authors: stoyanova r. Eur Urol Focus. 2024 Dec 10:S2405-4569(24)00256-6. doi: 10.1016/j.euf.2024.11.012. Online ahead of print. Eur Urol Focus. 2024. PMID: 39665894
210 results